JP2019500876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500876A5 JP2019500876A5 JP2018535126A JP2018535126A JP2019500876A5 JP 2019500876 A5 JP2019500876 A5 JP 2019500876A5 JP 2018535126 A JP2018535126 A JP 2018535126A JP 2018535126 A JP2018535126 A JP 2018535126A JP 2019500876 A5 JP2019500876 A5 JP 2019500876A5
- Authority
- JP
- Japan
- Prior art keywords
- culture
- glycan
- monoclonal antibody
- man
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 10
- 150000004676 glycans Chemical class 0.000 claims 9
- 241000894007 species Species 0.000 claims 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 4
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 4
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 4
- -1 Man 8 glycan Chemical class 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000012526 feed medium Substances 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- JMUPMJGUKXYCMF-IWDIICGPSA-N n-[(2s,3r,4r,5s,6r)-2-[(2s,3s,4s,5s,6r)-2-[[(2r,3r,4s,5s,6s)-6-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(2r,3s,4r,5r)-5-acetamido-1,2,4-trihydroxy-6-oxohexan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-[(2r,3s,4s,5s,6r)-3-[(2s,3r,4r,5s,6r)-3-acetamido-4-h Chemical compound O[C@@H]1[C@@H](NC(C)=O)[C@H](O[C@@H]([C@H](O)[C@H](C=O)NC(=O)C)[C@H](O)CO)O[C@H](CO)[C@H]1O[C@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)NC(C)=O)O1 JMUPMJGUKXYCMF-IWDIICGPSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275384P | 2016-01-06 | 2016-01-06 | |
| US62/275,384 | 2016-01-06 | ||
| PCT/US2017/012349 WO2017120347A1 (en) | 2016-01-06 | 2017-01-05 | Modulation of afucosylated species in a monoclonal antibody composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500876A JP2019500876A (ja) | 2019-01-17 |
| JP2019500876A5 true JP2019500876A5 (enExample) | 2020-02-13 |
| JP6674028B2 JP6674028B2 (ja) | 2020-04-01 |
Family
ID=57944513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535126A Active JP6674028B2 (ja) | 2016-01-06 | 2017-01-05 | モノクローナル抗体組成物中のアフコシル化種の調節 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190161543A1 (enExample) |
| EP (1) | EP3400241B1 (enExample) |
| JP (1) | JP6674028B2 (enExample) |
| CN (1) | CN109153716A (enExample) |
| AU (1) | AU2017206006B2 (enExample) |
| CA (1) | CA3010598A1 (enExample) |
| MX (1) | MX2018008447A (enExample) |
| WO (1) | WO2017120347A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10376582B2 (en) | 2013-10-16 | 2019-08-13 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| AU2017213775A1 (en) | 2016-02-03 | 2018-08-16 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| SG11202009216YA (en) * | 2018-03-26 | 2020-10-29 | Amgen Inc | Total afucosylated glycoforms of antibodies produced in cell culture |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| JP2022514299A (ja) * | 2018-12-19 | 2022-02-10 | シージェン インコーポレイテッド | 抗体の制御されたフコシル化 |
| WO2021066772A1 (en) * | 2019-10-01 | 2021-04-08 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Cell culture medium for reducing fucosylation and basic variants in the production of antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US8227241B2 (en) | 2004-03-12 | 2012-07-24 | Unigene Laboratories, Inc. | Bacterial host cell for the direct expression of peptides |
| JP5442251B2 (ja) | 2005-05-26 | 2014-03-12 | サイトス バイオテクノロジー アーゲー | 拡張可能な発酵方法 |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| CN102076865B (zh) * | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
| PL2438171T3 (pl) * | 2009-06-02 | 2015-04-30 | Regeneron Pharma | Komórki z niedoborem fukozylacji |
| WO2010141855A1 (en) * | 2009-06-05 | 2010-12-09 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| WO2013114165A1 (en) * | 2012-01-30 | 2013-08-08 | Dr Reddy's Laboratories Limited | Process of obtaining glycoprotein composition with increased afucosylation content |
| NO2760138T3 (enExample) * | 2012-10-01 | 2018-08-04 | ||
| WO2015140700A1 (en) * | 2014-03-19 | 2015-09-24 | Dr. Reddy's Laboratories Limited | Cell culture process |
| MX2018004831A (es) * | 2015-11-02 | 2018-08-01 | Genentech Inc | Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina. |
-
2017
- 2017-01-05 JP JP2018535126A patent/JP6674028B2/ja active Active
- 2017-01-05 AU AU2017206006A patent/AU2017206006B2/en active Active
- 2017-01-05 MX MX2018008447A patent/MX2018008447A/es unknown
- 2017-01-05 CN CN201780015362.XA patent/CN109153716A/zh active Pending
- 2017-01-05 US US16/067,193 patent/US20190161543A1/en not_active Abandoned
- 2017-01-05 CA CA3010598A patent/CA3010598A1/en active Pending
- 2017-01-05 EP EP17702444.5A patent/EP3400241B1/en not_active Revoked
- 2017-01-05 WO PCT/US2017/012349 patent/WO2017120347A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500876A5 (enExample) | ||
| Carrillo-Cocom et al. | Amino acid consumption in naive and recombinant CHO cell cultures: producers of a monoclonal antibody | |
| JP6982578B2 (ja) | 細胞培養培地 | |
| Padawer et al. | Case study: an accelerated 8‐day monoclonal antibody production process based on high seeding densities | |
| BRPI0514680A (pt) | produção de anticorpos anti-amilóide beta | |
| RU2642285C1 (ru) | Способ получения целевого антитела с модулированным галактозилированием (варианты) и способ модулирования галактозилирования целевого антитела (варианты) путем оптимизации культуральной среды | |
| RU2008152449A (ru) | Получение гликопротеинов | |
| IL201395A (en) | Multi-clonal cell lines and methods for generating multi-clonal cell lines | |
| NZ701825A (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| JP2019505164A5 (enExample) | ||
| UA120048C2 (uk) | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) | |
| JP2016513478A5 (enExample) | ||
| MX2018008447A (es) | Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal. | |
| JP2016523910A5 (enExample) | ||
| IL313983A (en) | Fully fucose-free glycoforms of antibodies are produced in cell culture | |
| CN104560882A (zh) | 一种降低酸性变体含量的cho细胞培养工艺 | |
| Amribt et al. | Optimization and robustness analysis of hybridoma cell fed-batch cultures using the overflow metabolism model | |
| IL307155B1 (en) | Antibodies with modulated glycan profiles | |
| GB0321100D0 (en) | Biological products | |
| Lin et al. | Enhancing the yield and activity of defucosylated antibody produced by CHO-K1 cells using Cas13d-mediated multiplex gene targeting | |
| Lee et al. | Effect of hypoosmotic pressure on cell growth and antibody production in recombinant Chinese hamster ovary cell culture | |
| Shi et al. | Controlled growth of Chinese hamster ovary cells and high expression of antibody-IL-2 fusion proteins by temperature manipulation | |
| Mahboudi et al. | The role of different supplements in expression level of monoclonal antibody against human CD20 | |
| Fan et al. | Effect of culture temperature on TNFR-Fc productivity in recombinant glutamine synthetase-chinese hamster ovary cells | |
| Clincke et al. | Effect of iron sources on the glycosylation macroheterogeneity of human recombinant IFN-γ produced by CHO cells during batch processes |